| Market Cap | 2.75B | P/E | - | EPS this Y | 31.40% | Ern Qtrly Grth | - |
| Income | -334.62M | Forward P/E | -10.13 | EPS next Y | 68.30% | 50D Avg Chg | -7.00% |
| Sales | 266.72M | PEG | 0.08 | EPS past 5Y | - | 200D Avg Chg | -19.00% |
| Dividend | N/A | Price/Book | 2.62 | EPS next 5Y | -77.40% | 52W High Chg | -49.00% |
| Recommedations | 1.60 | Quick Ratio | 4.29 | Shares Outstanding | 99.21M | 52W Low Chg | 30.00% |
| Insider Own | 1.83% | ROA | -20.86% | Shares Float | 887.81M | Beta | 1.12 |
| Inst Own | 44.47% | ROE | -36.34% | Shares Shorted/Prior | 4.08M/3.66M | Price | 27.26 |
| Gross Margin | -35.61% | Profit Margin | -125.46% | Avg. Volume | 597,895 | Target Price | 54.12 |
| Oper. Margin | -188.34% | Earnings Date | May 7 | Volume | 669,182 | Change | -7.09% |
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.
| Citigroup | Buy | Feb 29, 24 |
| Morgan Stanley | Overweight | Dec 14, 23 |
| JP Morgan | Overweight | Nov 30, 23 |
| Citigroup | Buy | Oct 26, 23 |
| Goldman Sachs | Buy | Oct 26, 23 |
| JP Morgan | Overweight | Oct 17, 23 |
| Cantor Fitzgerald | Overweight | Oct 9, 23 |
| Cantor Fitzgerald | Overweight | Sep 18, 23 |
| Cantor Fitzgerald | Overweight | Aug 10, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Amado Rafael | See Remarks See Remarks | Dec 29 | Sell | 26.3 | 19,363 | 509,247 | 22,637 | 01/03/24 |
| Du Ying | Chairperson & CEO Chairperson & CEO | Jan 01 | Sell | 26.12 | 8,380 | 218,886 | 1,133,450 | 01/03/24 |
| Reinhart Harald | See Remarks See Remarks | Jan 01 | Sell | 26.12 | 4,803 | 125,454 | 46,060 | 01/03/24 |
| Edmondson Frazor Titus III | Chief Legal Officer Chief Legal Officer | Jan 01 | Sell | 26.12 | 4,803 | 125,454 | 30,005 | 01/03/24 |
| Smiley Joshua L | See Remarks See Remarks | Dec 14 | Buy | 29.9 | 4,000 | 119,600 | 20,527 | 12/18/23 |
| Smiley Joshua L | See Remarks See Remarks | Nov 16 | Buy | 26.93 | 5,000 | 134,650 | 16,527 | 11/16/23 |
| WIRTH PETER | Director Director | Dec 08 | Sell | 35.35 | 7,852 | 277,568 | 12/09/22 | |
| Reinhart Harald | See Remarks See Remarks | Apr 01 | Option | 3 | 1,854 | 5,562 | 26,715 | 11/17/22 |
| Reinhart Harald | See Remarks See Remarks | Apr 01 | Sell | 40.02 | 1,854 | 74,197 | 24,861 | 11/17/22 |
| Edmondson Frazor Titus III | Chief Legal Officer Chief Legal Officer | Aug 17 | Option | 43.52 | 4,850 | 211,072 | 9,146 | 08/19/22 |
| DIEKMAN JOHN D | Director Director | Feb 04 | Sell | 50.17 | 1,000 | 50,170 | 67,615 | 02/07/22 |
| Lis William | Director Director | Jan 20 | Sell | 53.40 | 1,926 | 102,848 | 34,114 | 01/21/22 |
| Fu Tao | President & COO President & COO | Oct 28 | Sell | 104.81 | 10,000 | 1,048,100 | 77,500 | 10/29/21 |
| Fu Tao | President & COO President & COO | Oct 14 | Sell | 102.79 | 10,000 | 1,027,900 | 87,500 | 10/14/21 |
| Fu Tao | President & COO President & COO | Sep 16 | Sell | 129.22 | 9,900 | 1,279,278 | 207,600 | 09/16/21 |
| Fu Tao | President & COO President & COO | Sep 16 | Option | 18.92 | 10,000 | 189,200 | 217,500 | 09/16/21 |
| Reinhart Harald | Chief Medical Office.. Chief Medical Officer | Sep 08 | Sell | 148.75 | 10,000 | 1,487,500 | 09/08/21 | |
| Reinhart Harald | Chief Medical Office.. Chief Medical Officer | Sep 08 | Option | 3 | 10,000 | 30,000 | 10,000 | 09/08/21 |
| Du Ying | Chairwoman & CEO Chairwoman & CEO | Sep 08 | Sell | 149.07 | 29,785 | 4,440,050 | 1,008,653 | 09/08/21 |
| Du Ying | Chairwoman & CEO Chairwoman & CEO | Sep 03 | Sell | 146.2 | 81,326 | 11,889,861 | 1,038,438 | 09/03/21 |
| Du Ying | Chairwoman & CEO Chairwoman & CEO | Sep 03 | Option | 0.6 | 111,111 | 66,667 | 1,119,764 | 09/03/21 |
| Reinhart Harald | Chief Medical Office.. Chief Medical Officer | Aug 25 | Sell | 139.18 | 16,000 | 2,226,880 | 08/25/21 | |
| Reinhart Harald | Chief Medical Office.. Chief Medical Officer | Aug 25 | Option | 17.99 | 16,000 | 287,840 | 8,000 | 08/25/21 |
| Du Ying | Chairwoman & CEO Chairwoman & CEO | Aug 03 | Option | 0.6 | 111,111 | 66,667 | 1,116,649 | 08/03/21 |